Lupus retinopathy: epidemiology and risk factors.
Azevedo LGB, Biancardi AL, Silva RA, Tavares NDC, Abreu MM, Bica BERG, Moraes HV Jr.
Arq Bras Oftalmol. 2021 Jul-Aug;84(4):395-401. doi: 10.5935/0004-2749.20210076.
Hydroxychloroquine retinopathy.
Yusuf IH, Sharma S, Luqmani R, Downes SM.
Eye (Lond). 2017 Jun;31(6):828-845. doi: 10.1038/eye.2016.298. Epub 2017 Mar 10.
Hydroxychloroquine in systemic lupus erythematosus (SLE).
Ponticelli C, Moroni G.
Expert Opin Drug Saf. 2017 Mar;16(3):411-419. doi: 10.1080/14740338.2017.1269168. Epub 2016 Dec 14.
Purtscher-like retinopathy in systemic lupus erythematosus.
Ganne P, Slesser D, Syamala DD.
QJM. 2023 Mar 27;116(3):233-234. doi: 10.1093/qjmed/hcac249.
Systemic lupus erythematosus and ocular involvement: an overview.
Dammacco R.
Clin Exp Med. 2018 May;18(2):135-149. doi: 10.1007/s10238-017-0479-9. Epub 2017 Dec 14.
Retinal Arteriogenesis after Vaso-Occlusive Lupus Retinopathy.
Wakabayashi T, Hara C, Nishida K.
Ophthalmology. 2022 Oct;129(10):1191. doi: 10.1016/j.ophtha.2022.02.030. Epub 2022 Jun 23.
Lupus retinopathy: a marker of active systemic lupus erythematosus.
Seth G, Chengappa KG, Misra DP, Babu R, Belani P, Shanoj KC, Kumar G, Negi VS.
Rheumatol Int. 2018 Aug;38(8):1495-1501. doi: 10.1007/s00296-018-4083-4. Epub 2018 Jun 13.
Retinopathy in systemic lupus erythematosus: pathogenesis and approach to therapy.
Giorgi D, Pace F, Giorgi A, Bonomo L, Gabrieli CB.
Hum Immunol. 1999 Aug;60(8):688-96. doi: 10.1016/s0198-8859(99)00035-x.
Commentary: Systemic lupus erythematosus retinopathy: Eye or multisystem involvement?
Murugan SB, Somanath A.
Indian J Ophthalmol. 2023 May;71(5):1994-1995. doi: 10.4103/IJO.IJO_3386_22.
Purtscher-like retinopathy in systemic lupus erythematosus: clinical features, risk factors and prognosis.
Meng L, Yu Q, Zhao X, Chen L, Wang Y, Zhang W, Chen H, Chen Y.
QJM. 2023 Nov 24;116(11):923-932. doi: 10.1093/qjmed/hcad204.
